Leerink Partnrs Has Pessimistic View of BMY Q3 Earnings

Key Points

• Leerink Partners has lowered its Q3 2025 earnings per share estimate for Bristol Myers Squibb to $1.66 from $1.67, reflecting a cautious outlook on the company's financial performance.
• Bristol Myers Squibb reported $1.46 earnings per share for its latest quarter, exceeding the consensus estimate of $1.07, with a quarterly revenue of $12.27 billion.
• The company's recent dividend payout was $0.62 per share, which translates to an annualized amount of $2.48 and a dividend yield of 5.6%.

Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Equities research analysts at Leerink Partnrs reduced their Q3 2025 earnings per share estimates for shares of Bristol Myers Squibb in a report issued on Thursday, July 31st. Leerink Partnrs analyst D. Risinger now expects that the biopharmaceutical company will earn $1.66 per share for the quarter, down from their previous estimate of $1.67. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.74 per share. Leerink Partnrs also issued estimates for Bristol Myers Squibb's Q4 2025 earnings at $1.62 EPS, FY2026 earnings at $5.86 EPS and FY2029 earnings at $5.87 EPS.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.39. The company had revenue of $12.27 billion during the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%. The firm's quarterly revenue was up .6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.07 EPS.

A number of other brokerages have also recently issued reports on BMY. Piper Sandler started coverage on Bristol Myers Squibb in a report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price objective on the stock. UBS Group dropped their price objective on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a report on Friday, April 11th. Citigroup dropped their price objective on Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a report on Friday. Morgan Stanley reissued a "hold" rating on shares of Bristol Myers Squibb in a report on Thursday. Finally, The Goldman Sachs Group reissued a "neutral" rating and set a $55.00 price objective (down previously from $67.00) on shares of Bristol Myers Squibb in a report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $57.33.

Bristol Myers Squibb Stock Up 2.2%

BMY stock opened at $44.25 on Monday. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. The company has a market capitalization of $90.07 billion, a price-to-earnings ratio of 17.84, a PEG ratio of 2.33 and a beta of 0.36. Bristol Myers Squibb has a fifty-two week low of $42.96 and a fifty-two week high of $63.33. The stock has a fifty day moving average of $47.51 and a 200-day moving average of $52.23.

Institutional Investors Weigh In On Bristol Myers Squibb

Large investors have recently made changes to their positions in the business. Wellington Management Group LLP boosted its position in shares of Bristol Myers Squibb by 297.0% during the first quarter. Wellington Management Group LLP now owns 23,728,443 shares of the biopharmaceutical company's stock valued at $1,447,198,000 after purchasing an additional 17,750,938 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in Bristol Myers Squibb by 59.9% in the fourth quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock worth $1,814,341,000 after acquiring an additional 12,011,983 shares in the last quarter. GQG Partners LLC boosted its holdings in Bristol Myers Squibb by 22,647.6% in the first quarter. GQG Partners LLC now owns 12,023,454 shares of the biopharmaceutical company's stock worth $733,310,000 after acquiring an additional 11,970,598 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in Bristol Myers Squibb by 701.2% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,470,106 shares of the biopharmaceutical company's stock worth $705,309,000 after acquiring an additional 10,913,708 shares in the last quarter. Finally, Nuveen LLC purchased a new position in shares of Bristol Myers Squibb in the first quarter worth $624,369,000. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd were given a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.6%. The ex-dividend date was Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 100.00%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.